Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
Authors:
Open Access
- 22 May 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 11, 120
Abstract
Alzheimer’s disease (AD) has been associated with dysregulation of brain cholesterol homeostasis. Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond the known role in the regulation of plasma low-density lipoprotein cholesterol, was first identified in the brain with a potential involvement in brain development and apoptosis. However, its role in the central nervous system (CNS) and in AD pathogenesis is still far from being understood. While in vitro and in vivo evidence led to controversial results, genetic studies apparently did not find an association between PCSK9 loss of function mutations and AD risk or prevalence. In addition, a potential impairment of cognitive performances by the treatment with the PCSK9 inhibitors, alirocumab and evolocumab, have been excluded, although ongoing studies with longer follow-up will provide further insights. PCSK9 is able to affect the expression of neuronal receptors involved in cholesterol homeostasis and neuroinflammation, and higher PCSK9 concentrations have been found in the cerebrospinal fluid (CSF) of AD patients. In this review article, we critically examined the science of PCSK9 with respect to its modulatory role of the mechanisms underlying the pathogenesis of AD. In addition, based on literature data, we made the hypothesis to consider brain PCSK9 as a negative modulator of brain cholesterol homeostasis and neuroinflammation and a potential pharmacological target for treatment.Keywords
Funding Information
- Amgen
This publication has 100 references indexed in Scilit:
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)PLOS ONE, 2013
- Membrane rafts in Alzheimer's disease beta-amyloid productionBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimerNature Immunology, 2009
- Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ ClearanceNeuron, 2009
- Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosisProceedings of the National Academy of Sciences, 2009
- Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyNature Reviews Neuroscience, 2009
- PCSK9 is required for the disposal of non‐acetylated intermediates of the nascent membrane protein BACE1EMBO Reports, 2008
- Clearance of amyloid-β by circulating lipoprotein receptorsNature Medicine, 2007
- Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous SystemJournal of Cerebral Blood Flow & Metabolism, 2007
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003